NEW YORK (360Dx) – Celcuity, a Minnesota-based manufacturer of cell culture-based personalized medicine products, has raised $5.75 million in a recent funding round.

The securities offered by the firm were debt and convertible promissory notes and the equity securities issuable upon conversion of such notes. The offering was not part of a business combination transaction, such as a merger, acquisition, or exchange offer, according to a filing with the US Securities and Exchange Commission.

On deadline, the firm did not respond to a request for comment.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.